- Home
- ATOS vs BCTX Comparison
ATOS vs BCTX Comparison
Compare ATOS & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATOS | BCTX |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 26.6M |
| IPO Year | 2010 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ATOS | BCTX |
|---|---|---|
| Price | $2.60 | $3.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $23.00 | ★ $40.00 |
| AVG Volume (30 Days) | 49.4K | ★ 85.3K |
| Earning Date | 05-13-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,758.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.63 |
| 52 Week High | $7.56 | $14.68 |
Technical Indicators
Market Signals| Indicator | ATOS | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.11 | 46.99 |
| Support Level | $0.58 | $3.27 |
| Resistance Level | $6.18 | $3.74 |
| Average True Range (ATR) | 0.16 | 0.23 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 85.94 | 25.00 |
Price Performance
Historical ComparisonAbout ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.